ArticleMolecular medicine reports2016
mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.Wiley interdisciplinary reviews. RNA · 2018Review
- Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delta-human epidermal growth factor receptor 2 (HER2) is a splice variant of HER2, which lacks 16 amino acids in the extracellular domain. The aim of the present study was to elucidate the expression of delta‑HER2 and its clinicopathological correlation in Japanese patients with HER2‑overexpressing breast cancer. A total of 40 cases of HER2‑overexpressing breast cancer were investigated. The mRNA expression levels of wild type (wt)‑HER2 and delta‑HER2 were quantitated by quantitative polymerase chain reaction using RNA extracted from formalin‑fixed paraffin‑embedded specimens. In addition, the activated form of phosphorylated‑SRC (pSRC) and Ki‑67 were detected by immunostaining. The mRNA expression levels of wt‑HER2 varied largely, and the mRNA levels of delta‑HER2 were correlated with those of wt‑HER2. Furthermore, the enhanced immunostaining of pSRC was detected in 15 cases. Unsupervised hierarchal clustering of wt‑HER2, delta‑HER2 and pSRC was used to separate the cases into three clusters. In the first cluster, the levels of wt‑HER2 and delta‑HER2 were low, and pSRC immunostaining was low. Two other clusters were characterized by moderately and highly increased levels of wt‑HER2 and delta‑HER2 mRNA expression and enhanced pSRC. The delta/wt ratio was higher in the first cluster. Positive lymph node status and recurrence were more frequent in the first cluster compared with those in the two other clusters. Furthermore, the delta/wt ratio was significantly increased in lymph node‑positive and recurrent cases, compared with in lymph node‑negative and non‑recurrent cases. The present study demonstrated that delta-HER2 was expressed in Japanese patients with HER2‑overexpressing breast cancer. High mRNA expression levels of delta-HER2 were associated with pSRC and increased proliferation of tumor cells. A poor prognosis may be predicted by the increase in delta/wt ratio in HER2-overexpressing breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.